Loading…
← CockpitCompetitor Analysis › 087010.KS Peptron, Inc.Open in the cockpit ↗

Peptron, Inc.087010.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Biotechnology

Korean biotech specializing in long-acting drug delivery (sustained-release peptide/protein formulations), including Parkinson's and diabetes candidates.

Momentum laggard 4
Mkt cap
$1.49B
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$10.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-28.1 pp
WACC 6.3%
Hurdle
n/a
no reverse DCF
Close · KRW₩84,100
1D-5.7%
1W-15.1%
1M-16.9%
3M-56.6%
6M-68.4%
YTD-66.9%
1Y-66.6%
ATR %10.4%
52w lowhigh78.6% off high

What Peptron does

Korean biotech specializing in long-acting drug delivery (sustained-release peptide/protein formulations), including Parkinson's and diabetes candidates.

Products and services

  • SmartDepot long-acting delivery platform
  • PT320 (Parkinson's, exenatide)
  • Long-acting GLP-1/other formulations

Customers

  • Pharma licensing partners

Where it sits in the supply chain

  • Biotechnology
  • Drug-delivery platform technology
  • Long-acting injectable formulations

What could go right

  • Licensing deals for delivery platform
  • GLP-1/obesity drug demand

What could go wrong

  • Clinical trial failure risk
  • Reliance on partner licensing deals

Moat: narrow (IP / patents). Proprietary long-acting microsphere depot technology applied across licensed drug candidates.

Headquarters: Daejeon, South Korea · Founded: 1997 · Employees: 163

Named competitors

Peptron at a glance

Size Peptron (087010.KS) is a South Korea Health Care company (Biotechnology) with a market value of $1.49B, the 174th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩84,100 on 18 Nov 2026.

Performance Over six months the shares fell 68.4%, against -6.9% for the median peer and -37.2% for the South Korea market (cap-weighted) — lowest of 20 in its peer set.

Growth Revenue fell 12.6% over the last twelve months (peer median +28.0%); the operating margin is -488.1% (peer median -9.6%).

Valuation It trades at 359.6× enterprise value to sales against a peer median of 10.1× (4th most expensive of 18).

Capital Return on invested capital runs 28.1 points below its cost of capital (6.3% WACC).

Relative performance

5010021 May 202621 Aug 202618 Nov 2026Peer median 92087010.KS 32
Six months, rebased to 100: Peptron against the median of its 20 peers (local-currency closes).

Peptron financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩5.41B₩5.63B₩3.15B₩3.34B₩5.81B
Revenue growth—+79%-6%-43%—
Gross profit-₩964M₩760M-₩1.58B-₩1.75B-₩1.47B
EBITDA-₩23.2B-₩18.5B-₩13.8B-₩14.3B-₩10.7B
Net income-₩27.8B-₩13.8B-₩22.0B-₩15.9B-₩15.1B
Free cash flow-₩30.9B-₩23.1B-₩13.8B-₩11.7B-₩13.2B
Capital expenditure₩15.1B₩3.00B₩2.16B₩869M₩1.72B
Total debt₩31.2B₩29.6B₩9.24B₩9.13B₩9.23B

Quarterly statements and history in the cockpit →

Peptron competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-50%0%+50%MSB688319KRSAURGN688765PGENNRIXIMCR688105ABSIANABRAPPPPGN6881854588087010.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Peptron is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%0×500×1,000×MSB688319KRSAURGN688765PGENNRIXQUREVIRABSI4588087010.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Peptron is the large dot.

Peptron competitors and peer comparison

Head to head with its named competitors (087010.KS vs 128940.KS vs ALKS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Peptron 087010.KS$1.49B-68%-13%-488%359.6×n/a
HanmiPharm 128940.KS$3.95B-2%+14%16%3.3×4.7%
Alkermes Public ALKS$7.87B+27%+15%5%5.0×32.5%

How Peptron compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Peptron against its 20 peers (data as of 18 Nov 2026)
Measure087010.KSPeer medianRank in peer set
1-month return-16.9%-10.2%6th lowest of 21
6-month return-68.4%-6.9%lowest of 20
Distance from 52-week high-78.6%-44.1%lowest of 21
Revenue growth (TTM)-12.6%+28.0%3rd lowest of 18
Operating margin-488.1%-9.6%5th lowest of 19
EV / Sales359.6×10.1×4th most expensive of 18
ROIC minus cost of capital-28.1 pp-9.5 pp4th lowest of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%359.6×n/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%12.8×n/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%13.1×n/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%n/an/an/a
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%1,058.7×n/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%6.3×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%205.0×n/an/a
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a
Precigen PGENUnited States$1.53B0%+2,388%21%10.1×n/an/a
Nurix Therapeutics NRIXUnited States$1.54B-14%+739%41%0.8×n/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%2.3×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%4.9×39.4%-2.5%
uniQure QUREUnited States$1.42B-17%+28%-1,027%65.4×n/an/a
Vir Biotechnology VIRUnited States$1.57B+3%+1,696%-70%4.0×n/an/a
Absci ABSIUnited States$1.41B+65%-47%-9,155%835.7×n/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%7.9×0.5%+25.6%
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%50.1×n/an/a
PolyPeptide PPGN.SWSwitzerland$1.61B+7%+22%7%3.4×n/an/a
CanSino Biologics 688185.SSChina$1.38B0%+30%-4%6.6×n/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%408.9×n/an/a

Questions

Who are Peptron's main competitors?
Named competitors: Hanmi Pharm (128940.KS), Alkermes (ALKS). The cockpit's measured peer set (industry) also includes Mesoblast (MSB.AX), TLC BioSciences (7924.TWO), Chengdu Olymvax Biopharmaceuticals (688319.SS), Fujian Haixi Pharmaceuticals (2637.HK), Korsana Biosciences (KRSA), UroGen Pharma (URGN).
Is Peptron expensive compared with its peers?
On ev / sales it trades at 359.6× against a peer median of 10.1×, 4th most expensive of 18 in its peer set.
How has Peptron stock performed?
Over six months to 18 Nov 2026 the shares returned -68.4% against -6.9% for the median peer; over one year -66.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.